A Phase 1b/2a Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in B-Cell Cancers
Cancer is a leading cause of death in California. Many cancers resist current therapies due to therapy-resistant cancer stem cells (CSCs). A team at UCSD is testing an antibody therapy called cirmtuzumab in a clinical trial study to treat a blood cancer, Chronic Lymphocytic Leukemia (CLL). The antibody recognizes and attaches to a protein on the surface of cancer stem cells. This attachment disables the protein which slows the growth of the leukemia and makes it more vulnerable to anti-cancer drugs. The team is also testing cirmtuzumab in combination with an approved cancer fighting drug called ibrutinib, to target can- cer stem cells in a separate clinical trial. The aim is that combining cirmtuzumab with ibrutinib will improve cancer remission and long-term cancer control in patients.
Open label. Phase 1b dose finding, followed by Phase 2a.
Evaluate dosing and complete response rate.
News about this clinical trial:
- State’s Stem Cell Agency Awards $18.2 Million Grant for B Cell Cancer Clinical Trial
- UCSD cancer clinical trial gets $18.2 million